TAVANTA THERAPEUTICS
Dead / Abandoned — Abandoned — failure to respond (as of 08 Jul 2024)
What this means for you
This application is over — abandoned 24 Jun 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88916847
- Mark type
- Stylized text
- Filed
- 14 May 2020
- Published for opposition
- 13 Oct 2020
- Abandoned
- 24 Jun 2024
- Attorney of record
- Thomas G. Peterson
Goods and services
- Class 005 — Pharmaceuticals: Housemark for a full line of prescription pharmaceuticals for the treatment of cancer, multiple sclerosis, cystic fibrosis, and tuberous sclerosis complex; pharmaceuticals for treatment of cancer, multiple sclerosis, cystic fibrosis, and tuberous sclerosis complex; pharmaceuticals exhibiting efficient drug release for the treatment of cancer, multiple sclerosis, cystic fibrosis, and tuberous sclerosis complex
Owner
- TAVANTA THERAPEUTICS, INC., RADNOR, PA, US
- Druggability Technologies Holdings, Ltd, Dublin, IE
- Druggability Technologies Holdings, Ltd, Dublin, IE
Prosecution history
- 08 Jul 2024 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 08 Jul 2024 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 19 Mar 2024 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 19 Mar 2024 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 22 Dec 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 22 Dec 2023 — NON-FINAL ACTION E-MAILED
- 22 Dec 2023 — SU - NON-FINAL ACTION - WRITTEN
- 13 Dec 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 08 Dec 2023 — USE AMENDMENT FILED
- 08 Dec 2023 — TEAS STATEMENT OF USE RECEIVED
- 15 Sept 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Sept 2023 — SOU EXTENSION 5 GRANTED
- 08 Jun 2023 — SOU EXTENSION 5 FILED
- 08 Sept 2023 — NOTICE OF REVIVAL - E-MAILED
- 08 Sept 2023 — SOU EXTENSION RECEIVED WITH TEAS PETITION